Quick Answer
Camp4 Therapeutics Corp reported Net Income Loss of -$80.40 million for the year ending 2025.
- Camp4 Therapeutics Corp showed a decrease of -55.2% in Net Income Loss from 2024 to 2025.
- This data is from Camp4 Therapeutics Corp's annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$12.51 million | Q2 2023: -$12.10 million | Q3 2023: -$11.70 million | Q1 2024: -$12.46 million | Q2 2024: -$12.57 million | Q3 2024: -$13.48 million | Q1 2025: -$12.43 million | Q2 2025: -$12.59 million | Q3 2025: -$15.10 million.
- Over the full 3 years of available data (2023 to 2025), Camp4 Therapeutics Corp's Net Income Loss has declined by 63.1%.
- Historical annual values: Fiscal year 2025: -$80.40 million | Fiscal year 2024: -$51.79 million | Fiscal year 2023: -$49.29 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: